CELU (Celularity Inc.) stock: $1.31, $37.9M market cap, $6.2M cash, $31.7M EV, $80.8M fully diluted market cap. Data from Fully Diluted's biotech stocks database.
Pipeline assets
cenplacel-L
Phase 2 · Active Modality: Cell therapy (placental-derived allogeneic)
Indications- Aging/longevity; age-related degenerative diseases (immune, infectious, cancer) (Phase 2)
Status note MLASC (maternal leukocyte and stromal cell) candidate. Filing cites 'encouraging clinical data in Phase 1 and Phase 2 studies' and says the company is selectively advancing programs with a focus on longevity applications. (Note: latest available filing is the 10-Q for the period ended 2025-09-30.)
CYNK-001
Stage not disclosed · Active Modality: Cell therapy (placental-derived allogeneic NK cells)
Partnerships Dragasac: exclusive distribution and manufacturing agreement covering CYNK-001 (clinical/investigational/near-term commercial products); Genting Innovation: distribution and manufacturing rights incl. CYNK-001
Indications- Aging and other non-oncology indications (Stage not disclosed)
Status note Unmodified natural killer cell therapy. Filing references unmodified NK cell clinical trials under a contingent consideration agreement with Anthrogenesis; current clinical phase not stated in the 10-Q excerpts.
PSC-100
Stage not disclosed · Active Modality: Cell therapy (placental-derived allogeneic)
Partnerships Dragasac: exclusive distribution and manufacturing; Genting Innovation: distribution and manufacturing rights
Indications- Regenerative indications (Stage not disclosed)
Status note Listed as a cell therapy product in clinical development/investigational/near-term commercial use; indication and stage not stated in the 10-Q excerpts.
PDA-001
Stage not disclosed · Active Modality: Cell therapy (placental-derived allogeneic)
Partnerships Dragasac: exclusive distribution and manufacturing; Genting Innovation: distribution and manufacturing rights
Indications- Regenerative indications (Stage not disclosed)
Status note Listed as a cell therapy product in clinical development/investigational/near-term commercial use; indication and stage not stated in the 10-Q excerpts.
PDA-002
Stage not disclosed · Active Modality: Cell therapy (placental-derived allogeneic)
Partnerships Dragasac: exclusive distribution and manufacturing; Genting Innovation: distribution and manufacturing rights
Indications- Regenerative indications (Stage not disclosed)
Status note Listed as a cell therapy product in clinical development/investigational/near-term commercial use; indication and stage not stated in the 10-Q excerpts.
pEXO-001
Stage not disclosed · Active Modality: Cell therapy (placental-derived allogeneic)
Partnerships Dragasac: exclusive distribution and manufacturing; Genting Innovation: distribution and manufacturing rights
Indications- Regenerative indications (Stage not disclosed)
Status note Listed as a cell therapy product in clinical development/investigational/near-term commercial use; indication and stage not stated in the 10-Q excerpts.
APPL-001
Stage not disclosed · Active Modality: Cell therapy (placental-derived allogeneic)
Partnerships Dragasac: exclusive distribution and manufacturing; Genting Innovation: distribution and manufacturing rights
Indications- Regenerative indications (Stage not disclosed)
Status note Listed as a cell therapy product in clinical development/investigational/near-term commercial use; indication and stage not stated in the 10-Q excerpts.
Per-asset detail extracted from the 10-Q filed 2025-11-14. Fields the filing does not state are marked "not disclosed" rather than filled from other sources.